Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
Targeted treatment of AML using T cell recruiting antibody constructs

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.06.19
Views: 470

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

Prof Marion Subklewe speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about using T cell recruiting antibody constructs for the treatment of AML.

She explains that so far T cell recruiting antibodies have been used to target surface antigens, but these have the limitation of not having a restricted expression profile.

To solve this problem, Prof Subklewe explains that they have been doing preclinical work with a novel T cell recruiting antibody construct which recognises an infracellular target antigen - WT1 - and so has a much more specific and restricted target antigen.

Prof Subklewe concludes by saying that she hopes this promising new information leads to a phase I trial.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation